Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Onassis Cardiac Surgery Centre | OTHER |
| Attikon Hospital | OTHER |
| MITERA Children's Hospital | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)
Adult patients with congenital heart disease (ACHD) represent a rapidly growing population due to the progress of surgical techniques and optimal medical management. Non-valvular atrial arrhythmias (AA) carries a significant burden for long-term morbidity and potentially mortality in ACHD patients. AA occur three times more frequently in ACHD compared to the general population. When complicating ACHD, AA convey a twofold increase in the risk for stroke, contributing to an up to 100-fold higher prevalence of stroke in the ACHD population compared to age-matched healthy controls. At present, the European Society of Cardiology (ESC) Guidelines suggest oral anticoagulation (OAC) in all adult patients with AA and intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle. In the remaining ACHD patients with AA, OAC is suggested if CHA2DS2-Vasc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score is ≥1 (Class of recommendation IIa, level of evidence C).
Non-vitamin K oral anticoagulants (NOACs) are increasingly preferred over vitamin-K antagonists (VKAs) in most clinical scenarios due to improved safety (with regard to intracranial and other major bleeding) and efficacy (prevention of embolic stroke or systemic embolism) along with the convenience they offer for patients and physicians (fixed dose, no food and drug interactions, no INR monitoring). On the other hand, scarce data is available on the use of NOAC in ACHD.
In order to address this gap in evidence, we propose a prospective multicenter single arm, observational cohort trial, which will provide data on the efficacy and safety of apixaban used for the prevention of thromboembolism in ACHD patients with AA.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adults with CHD & non-valvular atrial arrhythmias | Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Stroke, systemic or pulmonary arterial thromboembolism and intracardiac thrombosis. | The composite endpoint of all-cause stroke, systemic and pulmonary embolism and intracardiac thrombosis | up to 58 months |
| Major bleeding | Defined as clinically overt bleeding that is associated with:
| up to 58 months |
| Measure | Description | Time Frame |
|---|---|---|
| Transient ischemic attack | Defined as new neurologic symptoms or deficit lasting less than 24 hours with no new infarction on neuroimaging (if available). | up to 58 months |
| Myocardial infarction |
| Measure | Description | Time Frame |
|---|---|---|
| General quality of life | Assessed with questionnaire SF-36 | Baseline |
| Apixaban persistence | The proportion of patients who were on apixaban at enrolment and continued receiving apixaban at the end of the study period. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients with Congenital Heart Disease and Non-Valvular Atrial Arrhythmias who are routinely treated with apixaban (i.e., new or ongoing users) for stroke prevention at any health-care level in Greece
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Georgios Giannakoulas, MD, PhD | AHEPA University Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Attikon University Hospital | Athens | 12462 | Greece | |||
| Mitera Children's Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38565389 | Derived | Kartas A, Papazoglou AS, Moysidis DV, Despotopoulos S, Baroutidou A, Kosmidis D, Koutsakis A, Liori S, Apostolopoulou S, Frogoudaki A, Tzifa A, Galatas A, Alexandridis G, Spiridonidis E, Doundoulakis I, Karagiannidis E, Karvounis H, Ziakas A, Giannakoulas G. Use of apixaban in adults with congenital heart disease and atrial arrhythmias: The PROTECT-AR study. Int J Cardiol. 2024 Jul 1;406:131993. doi: 10.1016/j.ijcard.2024.131993. Epub 2024 Mar 31. | |
| 32963069 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006330 | Heart Defects, Congenital |
| D013923 | Thromboembolism |
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
Defined as the detection of a significant rise/fall of Troponin in association with symptoms of ischemia, ECG changes, proof of ischemia on imaging or intracoronary thrombus at angiography. [Fourth definition of myocardial infarction; European Society of Cardiology (ESC) 2018]
| up to 58 months |
| Death from cardiovascular causes | Cardiovascular deaths were classified as deaths due to: ischemic stroke, hemorrhagic stroke, systemic or pulmonary embolism, other cardiovascular (i.e., myocardial infarction, sudden death, heart failure) and unobserved deaths. | up to 58 months |
| Τhe composite of major and clinically relevant nonmajor bleeding | Clinically relevant nonmajor bleeding bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. | up to 58 months |
| Τhe composite of stroke, systemic or pulmonary arterial thromboembolism and intracardiac thrombosis, transient ischemic attack, myocardial infarction, or cardiovascular death | up to 58 months |
| up to 58 months |
| Apixaban adherence | Assessed by reviewing electronic pharmacy prescription data | up to 58 months |
| Athens |
| 15123 |
| Greece |
| Onassis Cardiac Surgery Centre | Athens | 17674 | Greece |
| AHEPA University Hospital | Thessaloniki | 54636 | Greece |
| Derived |
| Kartas A, Doundoulakis I, Ntiloudi D, Koutsakis A, Kosmidis D, Rampidis G, Apostolopoulou S, Frogoudaki A, Tzifa A, Avramidis D, Ntzoyvara O, Liori S, Mousiama T, Mouratoglou SA, Karvounis H, Giannakoulas G. Rationale and design of a prospective, observational, multicentre study on the safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias: the PROTECT-AR study. BMJ Open. 2020 Sep 22;10(9):e038012. doi: 10.1136/bmjopen-2020-038012. |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D001145 | Arrhythmias, Cardiac |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |